{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"Pharmascope \u00c9pisode 115: Ost\u00e9oporose: solidifier la prise en charge \u2013 partie 3","description":"Un nouvel \u00e9pisode du Pharmascope est maintenant disponible! Dans de ce 115\u00e8me \u00e9pisode, S\u00e9bastien, Nicolas et Isabelle terminent leur s\u00e9rie d\u2019\u00e9pisodes sur l\u2019ost\u00e9oporose. Dans cette troisi\u00e8me et derni\u00e8re partie, on aborde la prise en charge suite \u00e0 une fracture, les marqueurs du remodelage osseux, l\u2019ost\u00e9oporose induite par les corticost\u00e9ro\u00efdes et la prise concomitante de suppl\u00e9ments de calcium et de vitamine D lors de l\u2019utilisation d\u2019un traitement pharmacologique. Les objectifs pour cet \u00e9pisode sont les suivants:  Discuter de la prise en charge des patients qui ont subi une fracture de fragilisation Discuter de l\u2019utilit\u00e9 des marqueurs biochimiques du remodelage osseux R\u00e9sumer la prise en charge de l\u2019ost\u00e9oporose induite par les corticost\u00e9ro\u00efdes Conseiller ad\u00e9quatement la prise d\u2019un suppl\u00e9ment de calcium et de vitamine D aux patients prenant un traitement pharmacologique contre l\u2019ost\u00e9oporose  &amp;nbsp; Ressources pertinentes en lien avec l\u2019\u00e9pisode Qaseem A et coll; Clinical Guidelines Committee of the American College of Physicians. Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians. Ann Intern Med. 2023;176:224-38. National Osteoporosis Guideline Group \u2013 UK. Clinical Guideline for the Prevention and Treatment of Osteoporosis 2021. Septembre 2021. Moe S, Paige A, Allan GM. Osteoporosis in postmenopausal women. Can Fam Physician. 2021;67:346. Nayak S, Greenspan SL. Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis. J Am Geriatr Soc. 2017;65:490-95. National Institute for Health and Care Excellence (NICE). Osteoporosis: assessing the risk of fragility fracture. London; 2017. Papaioannou A et coll. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ. 2010;182:1864-73. Management of Osteoporosis in Postmenopausal Women: The 2021 Position Statement of The North American Menopause Society\u2019\u2019 Editorial Panel. Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause. 2021;28:973-97. Bessette L et coll. The care gap in diagnosis and treatment of women with a fragility fracture. Osteoporos Int. 2008;19:79-86. Deng J et coll. Pharmacological prevention of fractures in patients undergoing glucocorticoid therapies: a systematic review and network meta-analysis. Rheumatology. 2021;60:649-57. Calculateur FRAX Centre for Metabolic Bone Diseases. FRAX: Fracture Risk Assessment Tool. University of Sheffield, UK. Outil d\u2019aide \u00e0 la d\u00e9cision Mayo Foundation for Medical Education and Research. Bone Health Choice Decision Aid. Mayo Clinic, USA. ","author_name":"CFPCLearn","author_url":"https:\/\/gomainpro.ca\/practicaltalkspod\/","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/39037615\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/195459705"}